FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103993826> ?p ?o ?g. }

• W2103993826 endingPage "6260" @default.
• W2103993826 startingPage "6254" @default.
• W2103993826 abstract "Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of morbidity, mortality and health-care utilization in the elderly population. A theoretical model was built to assess the levels of vaccine effectiveness and vaccine costs for which a hypothetical RSV-vaccine for Dutch elderly could be cost-effective.Different vaccination strategies were evaluated by changing the levels of vaccine effectiveness and the willingness to pay per quality-adjusted life year gained (QALY). Outcome measures included direct medical costs, QALYs, life years gained, incremental cost-effectiveness ratios (ICERs) and the maximum total vaccination costs per individual (i.e. (vaccine price+administration costs)×nr of doses) while remaining cost-effective.Using base-case assumptions, it was estimated that vaccination of all persons 60 years and older would prevent 3402GP visits, 2989 antibiotic prescriptions, 535 hospitalizations and 249 deaths and would cost €73,261 per QALY, for a vaccine effectiveness of 70%. Vaccinating only the high risk population of 60 years and older would reduce the estimates to 2042GP visits, 2009 antibiotic prescriptions, 179 hospitalizations and 209 deaths and this reduced the cost per QALY to €34,796 per QALY. Using the same assumptions, the maximum total vaccination costs per individual ranged from €26 when vaccinating all persons 60 and older to €68 when vaccinating only persons aged 85 and above, using a willingness to pay threshold of €50,000 per QALY. For the high risk population aged 60 years and older the estimated maximum total vaccination costs ranged from €52 to €99.Vaccination of Dutch elderly against RSV was found cost-effective for several scenarios. As expected, vaccination is more likely to be cost-effective when only including persons who are at increased risk for contracting RSV or the potential complications of RSV. This theoretical study shows that based on the disease burden in the Dutch population aged 60yrs and older there is potential to develop a vaccine that might be considered cost-effective in the Netherlands." @default.
• W2103993826 created "2016-06-24" @default.
• W2103993826 creator A5016565734 @default.
• W2103993826 creator A5033079155 @default.
• W2103993826 creator A5043102407 @default.
• W2103993826 creator A5055751408 @default.
• W2103993826 creator A5064115635 @default.
• W2103993826 date "2013-12-01" @default.
• W2103993826 modified "2023-09-27" @default.
• W2103993826 title "RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population" @default.
• W2103993826 cites W1894593978 @default.
• W2103993826 cites W1913350003 @default.
• W2103993826 cites W1925238017 @default.
• W2103993826 cites W1968605303 @default.
• W2103993826 cites W1974542809 @default.
• W2103993826 cites W1975109518 @default.
• W2103993826 cites W1979871017 @default.
• W2103993826 cites W1982107565 @default.
• W2103993826 cites W1984578505 @default.
• W2103993826 cites W1989501142 @default.
• W2103993826 cites W1993046061 @default.
• W2103993826 cites W2000129666 @default.
• W2103993826 cites W2013108239 @default.
• W2103993826 cites W2013400583 @default.
• W2103993826 cites W2013627456 @default.
• W2103993826 cites W2034777197 @default.
• W2103993826 cites W2034781418 @default.
• W2103993826 cites W2035118895 @default.
• W2103993826 cites W2046056354 @default.
• W2103993826 cites W2059424469 @default.
• W2103993826 cites W2060132446 @default.
• W2103993826 cites W2078523426 @default.
• W2103993826 cites W2084685889 @default.
• W2103993826 cites W2093536586 @default.
• W2103993826 cites W2095069717 @default.
• W2103993826 cites W2096559685 @default.
• W2103993826 cites W2103637444 @default.
• W2103993826 cites W2104449254 @default.
• W2103993826 cites W2108273817 @default.
• W2103993826 cites W2108274821 @default.
• W2103993826 cites W2117122572 @default.
• W2103993826 cites W2119964825 @default.
• W2103993826 cites W2123817481 @default.
• W2103993826 cites W2127448855 @default.
• W2103993826 cites W2139841187 @default.
• W2103993826 cites W2169722090 @default.
• W2103993826 cites W2171346729 @default.
• W2103993826 cites W2290245777 @default.
• W2103993826 doi "https://doi.org/10.1016/j.vaccine.2013.10.023" @default.
• W2103993826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24148573" @default.
• W2103993826 hasPublicationYear "2013" @default.
• W2103993826 type Work @default.
• W2103993826 sameAs 2103993826 @default.
• W2103993826 citedByCount "17" @default.
• W2103993826 countsByYear W21039938262013 @default.
• W2103993826 countsByYear W21039938262016 @default.
• W2103993826 countsByYear W21039938262017 @default.
• W2103993826 countsByYear W21039938262018 @default.
• W2103993826 countsByYear W21039938262019 @default.
• W2103993826 countsByYear W21039938262021 @default.
• W2103993826 countsByYear W21039938262022 @default.
• W2103993826 countsByYear W21039938262023 @default.
• W2103993826 crossrefType "journal-article" @default.
• W2103993826 hasAuthorship W2103993826A5016565734 @default.
• W2103993826 hasAuthorship W2103993826A5033079155 @default.
• W2103993826 hasAuthorship W2103993826A5043102407 @default.
• W2103993826 hasAuthorship W2103993826A5055751408 @default.
• W2103993826 hasAuthorship W2103993826A5064115635 @default.
• W2103993826 hasConcept C112930515 @default.
• W2103993826 hasConcept C127454912 @default.
• W2103993826 hasConcept C160735492 @default.
• W2103993826 hasConcept C162324750 @default.
• W2103993826 hasConcept C187212893 @default.
• W2103993826 hasConcept C18903297 @default.
• W2103993826 hasConcept C203014093 @default.
• W2103993826 hasConcept C22070199 @default.
• W2103993826 hasConcept C2780441014 @default.
• W2103993826 hasConcept C2908647359 @default.
• W2103993826 hasConcept C3019080777 @default.
• W2103993826 hasConcept C50522688 @default.
• W2103993826 hasConcept C515549039 @default.
• W2103993826 hasConcept C64332521 @default.
• W2103993826 hasConcept C71924100 @default.
• W2103993826 hasConcept C86803240 @default.
• W2103993826 hasConcept C99454951 @default.
• W2103993826 hasConceptScore W2103993826C112930515 @default.
• W2103993826 hasConceptScore W2103993826C127454912 @default.
• W2103993826 hasConceptScore W2103993826C160735492 @default.
• W2103993826 hasConceptScore W2103993826C162324750 @default.
• W2103993826 hasConceptScore W2103993826C187212893 @default.
• W2103993826 hasConceptScore W2103993826C18903297 @default.
• W2103993826 hasConceptScore W2103993826C203014093 @default.
• W2103993826 hasConceptScore W2103993826C22070199 @default.
• W2103993826 hasConceptScore W2103993826C2780441014 @default.
• W2103993826 hasConceptScore W2103993826C2908647359 @default.
• W2103993826 hasConceptScore W2103993826C3019080777 @default.
• W2103993826 hasConceptScore W2103993826C50522688 @default.
• W2103993826 hasConceptScore W2103993826C515549039 @default.

• next